产品名称
抗 SIGLEC15 兔抗, affinity isolated antibody
biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
mol wt
36 kDa
species reactivity
human, rat, mouse
concentration
1 mg/mL
technique(s)
ELISA: suitable
immunohistochemistry: suitable
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... SIGLEC15(284266)
Biochem/physiol Actions
唾液酸结合性免疫球蛋白样凝集素15（SIGLEC15）可以识别称为唾液酸-Tn（sTn）抗原的肿瘤相关聚糖结构。它在肿瘤组织中与肿瘤相关的巨噬细胞中表达。该蛋白质可充当信号转导子。SIGLEC15可与12kDa的衔接子蛋白DNAX激活蛋白（DAP12）结合，并将信号转导至脾酪氨酸激酶（Syk）。
Disclaimer
除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
Features and Benefits
完放心地使用我们的抗体。如果抗体在您的申请的研究中不起作用，我们将全额退款或安排替代抗体。了解更多信息。
General description
唾液酸结合性免疫球蛋白样凝集素15（SIGLEC15）是聚糖识别蛋白Siglec家族的一部分。它在巨噬细胞的子类中表达。这种I型跨膜蛋白具有两个免疫球蛋白样结构域，一个跨膜结构域和一个短的胞质尾巴。SIGLEC15基因位于人类染色体18q12.3上。
Immunogen
该抗体通过靶向人SIGLEC15的氨基末端附近的15个氨基酸多肽获得。
Other Notes
可以使用阻断肽 SBP3500654阻断该抗体的作用。
Physical form
以1 mg/mL浓度，溶于含0.02％叠氮化钠的PBS溶液的形式提供。
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
常规特殊物品
此项目有
The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-? secretion from monocytes/macrophages through the DAP12-Syk pathway.
Takamiya R
Glycobiology (2013)
Xiaoting Chen et al.
Heliyon, 10(3), e25266-e25266 (2024-02-14)
Laryngeal squamous cell carcinoma (LSCC) is the ultimate common malignant head and neck cancer with dismal prognosis. The expression pattern and clinical significance of Siglec-15 (Sialic acid-binding immunoglobulin-like lectin 15) in LSCC are poorly understood. In order to lay the
Siglec-15: an immune system Siglec conserved throughout vertebrate evolution.
Glycobiology (2007)
Kaiqin Sheng et al.
International journal of molecular sciences, 24(1) (2023-01-09)
Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) has been identified as a crucial immune suppressor in human cancers, comparable to programmed cell death 1 ligand (PD-L1). However, the regulatory mechanisms underlying its transcriptional upregulation in human cancers remain largely unknown. Here
Yun-Long Wang et al.
American journal of cancer research, 11(5), 2291-2302 (2021-06-08)
Siglec15 is a recently characterized immunosuppressive transmembrane protein, which expresses in various types of solid tumors and promotes cancer development. Several studies reported that Siglec15 is a prognostic biomarker of cancer patients, and targeting Siglec15 may be a promising strategy
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持